Ultragenyx Pharmaceutical, Inc. (RARE)
15.65
-0.30
(-1.88%)
USD |
NASDAQ |
Oct 23, 16:00
15.64
-0.01
(-0.06%)
After-Hours: 20:00
Ultragenyx Pharmaceutical Enterprise Value : 2.446B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 2.446B |
| October 22, 2026 | 2.476B |
| October 21, 2026 | 2.473B |
| October 20, 2026 | 2.483B |
| October 19, 2026 | 2.389B |
| October 16, 2026 | 2.337B |
| October 15, 2026 | 2.399B |
| October 14, 2026 | 2.373B |
| October 13, 2026 | 2.375B |
| October 12, 2026 | 2.412B |
| October 09, 2026 | 2.430B |
| October 08, 2026 | 2.411B |
| October 07, 2026 | 2.372B |
| October 06, 2026 | 2.329B |
| October 05, 2026 | 2.333B |
| October 02, 2026 | 2.404B |
| October 01, 2026 | 2.358B |
| September 30, 2026 | 2.385B |
| September 29, 2026 | 2.414B |
| September 28, 2026 | 2.325B |
| September 25, 2026 | 2.333B |
| September 24, 2026 | 2.360B |
| September 23, 2026 | 2.371B |
| September 22, 2026 | 2.443B |
| September 21, 2026 | 2.348B |
| Date | Value |
|---|---|
| September 18, 2026 | 2.334B |
| September 17, 2026 | 2.333B |
| September 16, 2026 | 2.174B |
| September 15, 2026 | 2.193B |
| September 14, 2026 | 2.246B |
| September 11, 2026 | 2.314B |
| September 10, 2026 | 2.324B |
| September 09, 2026 | 2.315B |
| September 08, 2026 | 2.371B |
| September 04, 2026 | 2.412B |
| September 03, 2026 | 2.368B |
| September 02, 2026 | 3.516B |
| September 01, 2026 | 3.445B |
| August 31, 2026 | 3.386B |
| August 28, 2026 | 3.425B |
| August 27, 2026 | 3.489B |
| August 26, 2026 | 3.507B |
| August 25, 2026 | 3.509B |
| August 24, 2026 | 3.436B |
| August 21, 2026 | 3.447B |
| August 20, 2026 | 3.397B |
| August 19, 2026 | 3.487B |
| August 18, 2026 | 3.414B |
| August 17, 2026 | 3.477B |
| August 14, 2026 | 3.512B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AbbVie, Inc. | 569.05B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| BioMarin Pharmaceutical, Inc. | 14.17B |
| Ionis Pharmaceuticals, Inc. | 7.245B |
| Regeneron Pharmaceuticals, Inc. | 77.94B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -92.00M |
| Revenue (Quarterly) | 214.00M |
| Total Expenses (Quarterly) | 306.00M |
| EPS Diluted (Quarterly) | -0.9028 |
| Gross Profit Margin (Quarterly) | 80.37% |
| Profit Margin (Quarterly) | -42.99% |
| Earnings Yield | -37.33% |
| Normalized Earnings Yield | -37.36 |